X4 Pharmaceuticals (XFOR) Share-based Compensation (2017 - 2025)

X4 Pharmaceuticals' Share-based Compensation history runs 9 years deep, the most recent figure standing at $2.3 million for Q4 2025.

• Quarterly Share-based Compensation rose 2.44% year-over-year to $2.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.3 million (down 47.61% YoY) and the FY2025 annual result came in at $4.3 million, down 47.61% from the prior year.
• Share-based Compensation was $2.3 million for Q4 2025 at X4 Pharmaceuticals, up from $760000.0 in the prior quarter.
• Across five years, Share-based Compensation topped out at $5.2 million in Q4 2022 and bottomed at -$3.0 million in Q3 2022.
• A 5-year average of $1.7 million and a median of $1.8 million in 2024 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2022 — Share-based Compensation plunged 295.84% — and 2023, when it surged 13608.33%.
• X4 Pharmaceuticals' Share-based Compensation stood at $1.6 million in 2021, then surged by 222.37% to $5.2 million in 2022, then plunged by 51.05% to $2.5 million in 2023, then fell by 12.68% to $2.2 million in 2024, then gained by 2.44% to $2.3 million in 2025.
• Business Quant data shows XFOR's Share-based Compensation at $2.3 million in Q4 2025, $760000.0 in Q3 2025, and $748000.0 in Q2 2025.